An ACTH/MSH(4-9) analog counteracts the behavioral effects of a mineralocorticoid receptor antagonist

Pharmacol Biochem Behav. 1993 Feb;44(2):447-50. doi: 10.1016/0091-3057(93)90489-g.

Abstract

The ACTH/MSH(4-9) analog Org2766 has been demonstrated to counteract age-related behavioral and morphological parameters especially those related to hippocampal functioning. Hippocampal mineralocorticoid receptors (MRs) are known to decline in the senescent rat. This decrease can be also counteracted by a chronic treatment with an ACTH(4-9) analog. The apparent effect of the peptide on hippocampal functioning prompted us to study a possible interaction between ACTH and MRs at a behavioral level. A chronic treatment with the ACTH(4-9) analog prevented the behavioral alteration induced by a specific MR antagonist (RU28318; 100 ng/microliters, ICV) in the Morris water maze and a step-through avoidance task. A possible role for neuronal excitation, involving MR activation, in peptide-facilitated behavioral recovery as seen in lesion studies and aging is discussed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenocorticotropic Hormone / analogs & derivatives*
  • Adrenocorticotropic Hormone / pharmacology
  • Analysis of Variance
  • Animals
  • Avoidance Learning / drug effects*
  • Male
  • Mineralocorticoids*
  • Peptide Fragments / pharmacology*
  • Rats
  • Rats, Wistar
  • Receptors, Mineralocorticoid
  • Receptors, Steroid / antagonists & inhibitors
  • Receptors, Steroid / drug effects*
  • Spatial Behavior*
  • Spironolactone / analogs & derivatives*
  • Spironolactone / antagonists & inhibitors
  • Spironolactone / pharmacology

Substances

  • Mineralocorticoids
  • Peptide Fragments
  • Receptors, Mineralocorticoid
  • Receptors, Steroid
  • Spironolactone
  • Org 2766
  • RU 28318
  • Adrenocorticotropic Hormone